Patricia M. LoRusso

发表

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

P. LoRusso, R. Kurzrock, A. Naing, 2013, Investigational New Drugs.

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

K. Wilner, P. LoRusso, G. Schwartz, 2011, British Journal of Cancer.

BET inhibitors: a novel epigenetic approach

P. LoRusso, J. Eder, D. Doroshow, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients (pts) with advanced solid tumors (STs).

G. Shapiro, A. Zhu, E. Heath, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

J. Heymach, P. LoRusso, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

A. Tolcher, J. Soria, V. Diéras, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

J. Lunceford, P. LoRusso, A. Lockhart, 2016, Investigational New Drugs.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

K. Bible, R. Martell, Patricia M. LoRusso, 2008, Investigational new drugs.

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

M. Hidalgo, L. Sequist, R. Camidge, 2012 .

Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors.

A. Shields, S. Gadgeel, E. Heath, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

A. Tolcher, P. LoRusso, A. Patnaik, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Patricia M. LoRusso, Percy, A. Oza, 2008, Investigational New Drugs.

Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors

T. Holzer, P. LoRusso, M. Gounder, 2017, Investigational New Drugs.

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

G. Demetri, J. Ware, G. Shapiro, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

G. Demetri, J. Ware, P. LoRusso, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors.

E. Winer, P. LoRusso, M. Kosh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

R. Parchment, J. Boerner, S. Tolaney, 2016 .

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

R. Parchment, J. Boerner, S. Tolaney, 2016 .

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

R. Parchment, J. Boerner, S. Tolaney, 2016 .

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

R. Parchment, J. Boerner, S. Tolaney, 2016 .